糖尿病患者接受双时相门冬胰岛素30治疗时的临床基线情况——IMPROVE^TM研究中国亚组结果

目的选取IMPROVE^TM的中国亚组数据，了解中国糖尿病患者治疗时的基线特征。方法经临床医生判断预启用BIAsp30治疗的糖尿病患者为人选对象。由医生记录基线时的人口统计学数据、病史、起始BIAsp30治疗的原因、血糖控制情况和具体治疗方案。结果共人选糖尿病患者21729例（女性37％，男性63％），平均糖尿病病程（4．86±4．98）年，2型糖尿病（T2DM）患者占99．7％，平均年龄（54．0±12．7）岁，平均体重指数BMI（24．63±3．12）kg／m^2。24％的受试者患有大血管并发症；40．5％患有微血管并发症。基线时，32．3％的患者从未进行过降糖治疗，59．3％仅接受过口服降糖药（OHA）治疗，8．1％单独应用胰岛素或联合OHA治疗。受试者基线时平均糖化血红蛋白（HbA1c）为（9．46±2．04）％。转用BIAsp30治疗的最主要原因是期望改善血糖控制，89．1％的患者采用了每日2次的给药方式。结论中国糖尿病患者血糖控制差且并发症发生率高，糖尿病治疗尤其是胰岛素治疗的开展是滞后的。

The clinical baseline status of Chinese diabetic patients undergoing BIAsp 30 treatment: Data from china cohort of IMPROVETM

Objective To get information on the baseline status of Chinese diabetic patients using data from China cohort of IMPROVE^TM study. Methods Patients with diabetes who would initiate BIAsp30 at the decision of the physician were included. The physicians collected the baseline demographic data, medical histories and the reasons for starting BIAsp30 treatment, set the glycaemic targets and chose the regimens of treatment. Results A total of 21729 patients （female 37.2%, male 62.8 %） were included in the study. They had a mean diabetic duration of 4. 86±4. 98 years,99.7% of which had type 2 diabetes mellitus （T2DM）. The mean age was （54.0± 12.7） years. The mean body mass index （BMI） was （24. 63 ± 3.12） kg/m^2. About 24 percent of the subjects developed diabetic macrovascular complications, and 40.5 percent developed diabetic microvascular complication. At base line, 32.3 percent of the subjects had not taken any antidiabetic medications, 59.3 percent had only taken the oral hypoglycemic agents OHA, and 8.1 percent had got insulin therapy with or without OHA（s）. The mean glycosylated hemoglobin A1 c （HbA1 c） at baseline was （9.46±2.04）%. The main reason for initiation of BIAsp30 was to improve the glycaemic control. A twice-daily regimen was used to start BIAsp30 therapy for about 89.1 % of the patients. Conclusions The Chinese diabetic patients are under poor glycaemie control and high incidence of diabetic complications. The initiation of diabetic therapy, particularly insulin treatment, is commonly delayed in clinical practice.